Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Cantor report effect
View:
Post by Marcel49 on Nov 21, 2022 11:40am

Cantor report effect

Was just  a flash in the pan without any news from Th. Hope!
Comment by Biobob on Nov 21, 2022 11:52am
I mean some high profile analyst from NYC just told us Th is worth 12$ cdn and this is what we get 50 cents uptick and then it's back to same sh.t.  Honestly we're fuc..ed until they deliver something material.
Comment by SPCEO1 on Nov 21, 2022 7:07pm
Chill Biobob. Cantor's report was a nice step in the right direction but Cantor services mostly institutional investors and they really can't buy THTX in the open market due to the low market cap and low traidng volue. So, its impact is more psychological than anything else until a deal is done, at which point Cantor's clients might well be part of it since they could grab big chunks ...more  
Comment by LouisW on Nov 21, 2022 8:15pm
@SPCEO1 Since soleus and Morgan Stanley are increasing their position...Do you think they will write a report for THTX? 
Comment by SPCEO1 on Nov 21, 2022 11:45pm
Soleus is an asset manager so they do not publish their research but use it only internally at their firm. I am not certain but it appears Morgan Stanley's holding is not direct. I suspect the actual holders are one or more hedge funds that utilize Morgan Stanley as a custodian. If that is correct, we should not expect Morgan Stanley to write a report either as that operation is separate from ...more  
Comment by jfm1330 on Nov 22, 2022 9:04am
Still no news. All we have is indirect signs that something positive is going on, like the Cantor report or the renewed job offer for a global regulatory manager in oncology. Again, why hiring somebody to fill this position if your oncology trial is not minimally positive at this point? How would you convince somebody to leave a good job somewhere else to accept the job with Thera, only to end up ...more  
Comment by Lee430 on Nov 22, 2022 10:38am
Most likely no news on the holiday weeks of Thanksgiving, Christmas and through to the new year….So just a short window in December left for good news, sure looking like my plan to hold out for positive news before selling some THTX for my RMD this year was a bad call :-<
Comment by SPCEO1 on Nov 22, 2022 11:00am
You still have some time left so don't throw in the towel yet! 
Comment by yureja22 on Nov 22, 2022 1:30am
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities